AMENDMENTS TO THE CLAIMS

Please amend claims 18-22. The listing of claims below will replace all prior versions and listings of claims in the application. Deletions appear in ~~strikethrough font~~, and additions are underlined.

Complete listing of claims

Claims 1-11 (Cancelled)

12. (Previously Presented) A method for the treatment of depression or an anxiety state in a human in need thereof, comprising administering to said human an effective amount of an inhibitor of the t-PA-mediated activation of a glutamate receptor.

13. (Previously Presented) A method according to claim 12, wherein the glutamate receptor is of the NMDA type.

14. (Previously Presented) A method according to claim 12, wherein the inhibitor is a protease.

15. (Previously Presented) A method according to claim 14, wherein the protease is a serine protease inhibitor.

16. (Previously Presented) A method according to claim 15, wherein the serine protease inhibitor is chosen from neuroserpin, plasminogen activator inhibitor (PAI), and protease nexin I (PN-1).

17. (Previously Presented) A method according to claim 12, wherein the inhibitor is chosen from DSPA and a DSPA derivative, analog, or fragment.

18. (Currently Amended) A method according to claim 17, wherein the sequence of the DSPA or DSPA derivative, analog, or fragment is the amino acid sequence ~~shown in Figure 1~~ of SEQ ID NO:1 or has at least 70% homology with the sequence ~~shown in Figure 1~~ of SEQ ID NO:1.

19. (Currently Amended) A method according to claim 18, wherein the sequence of the DSPA or DSPA derivative, analog, or fragment has from 80 to 90% homology with the sequence ~~shown in Figure 1~~ of SEQ ID NO:1.

20. (Currently Amended) A method according to claim 17,

wherein a DSPA ~~having the amino acid sequence shown in Figure 1~~ is administered to ~~the~~ a human in a dose greater than ~~62.5~~60 and lower than 160 microgram/kg; ~~or~~

wherein the DSPA has the amino acid sequence of SEQ ID NO:1~~wherein a DSPA derivative, analog, or fragment is administered to the human in a dose adjusted accordingly, based on the bioequivalence of the DSPA derivative, analog, or fragment and a DSPA having the amino acid sequence shown in Figure 1~~.

21. (Currently Amended) A method according to claim 17,

wherein a DSPA or a DSPA derivative, analog, or fragment ~~having the amino acid sequence shown in Figure 1~~ is administered to ~~the~~ a human in a dose from 90 to 125 microgram/kg; ~~or~~

wherein the DSPA has the amino acid sequence of SEQ ID NO:1~~wherein a DSPA derivative, analog, or fragment is administered to the human in a dose adjusted accordingly, based on the bioequivalence of the DSPA derivative, analog, or fragment and the DSPA having the amino acid sequence shown in Figure 1~~.

22. (Currently Amended) A method according to claim 17,

wherein a DSPA or a DSPA derivative, analog, or fragment ~~having the amino acid sequence shown in Figure 1~~ is administered to ~~the~~ a human in a dose of about 90 microgram/kg; ~~or~~

wherein the DSPA has the amino acid sequence of SEQ ID NO:1~~wherein a DSPA derivative, analog, or fragment is administered to the human in a dose adjusted accordingly, based on the bioequivalence of the DSPA derivative, analog, or fragment and the DSPA having the amino acid sequence shown in Figure 1~~.

23. (Previously Presented) A method for the treatment of stroke in a human in need thereof comprising administering to said human an effective amount of a DSPA or a DSPA derivative, analog, or fragment and a thrombolytic.

24. (Previously Presented) A method according to claim 23, wherein the thrombolytic is t-PA.

25. (Previously Presented) A method for providing neuroprotection in a human in need thereof comprising administering to said human an effective amount of a DSPA or a DSPA derivative, analog, or fragment.

26. (Previously Presented) A method according to claim 25, wherein the method for providing neuroprotection is a method for the treatment or prophylaxis of a condition chosen from Parkinsonism, Alzheimer's, Huntington's chorea, diabetes, painful conditions, epilepsy, and memory disturbances.

27. (New) A method according to claim 17, wherein the DSPA derivative, analog, or fragment is administered to a human in a dose bioequivalent to the administration of a dose greater than 60 and lower than 160 microgram/kg of a DSPA having the amino acid sequence of SEQ ID NO:1.

28. (New) A method according to claim 17, wherein the DSPA derivative, analog, or fragment is administered to a human in a dose bioequivalent to the administration of a dose from 90 to 125 microgram/kg of a DSPA having the amino acid sequence of SEQ ID NO:1.

29. (New) A method according to claim 17, wherein the DSPA derivative, analog, or fragment is administered to a human in a dose bioequivalent to the administration of a dose of about 90 microgram/kg of a DSPA having the amino acid sequence of SEQ ID NO:1.